Cognition Therapeutics (CGTX) Competitors

$1.20 0.00 (0.00%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$1.20 0.00 (-0.33%)

As of 07:01 AM Eastern

CGTX vs. CGC, AURA, AVIR, NMRA, and PRTC

Should you buy Cognition Therapeutics stock or one of its competitors? MarketBeat compares Cognition Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cognition Therapeutics include Canopy Growth (CGC), Aura Biosciences (AURA), Atea Pharmaceuticals (AVIR), Neumora Therapeutics (NMRA), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical products" industry.

How does Cognition Therapeutics compare to Canopy Growth?

Cognition Therapeutics (NASDAQ:CGTX) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Cognition Therapeutics has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market. Comparatively, Canopy Growth has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

In the previous week, Cognition Therapeutics had 3 more articles in the media than Canopy Growth. MarketBeat recorded 10 mentions for Cognition Therapeutics and 7 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 0.79 beat Cognition Therapeutics' score of 0.50 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Canopy Growth	2 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Cognition Therapeutics has higher earnings, but lower revenue than Canopy Growth. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
Canopy Growth	$225.65M	1.92	-$429.86M	-$1.30	N/A

Cognition Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -94.39%. Canopy Growth's return on equity of -46.85% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
Canopy Growth	-94.39%	-46.85%	-28.95%

43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 3.3% of Canopy Growth shares are held by institutional investors. 14.4% of Cognition Therapeutics shares are held by insiders. Comparatively, 0.2% of Canopy Growth shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cognition Therapeutics currently has a consensus price target of $3.33, suggesting a potential upside of 177.78%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cognition Therapeutics is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Canopy Growth	2 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cognition Therapeutics beats Canopy Growth on 10 of the 15 factors compared between the two stocks.

How does Cognition Therapeutics compare to Aura Biosciences?

Cognition Therapeutics (NASDAQ:CGTX) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

Cognition Therapeutics has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

In the previous week, Aura Biosciences had 8 more articles in the media than Cognition Therapeutics. MarketBeat recorded 18 mentions for Aura Biosciences and 10 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.50 beat Aura Biosciences' score of -0.65 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aura Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Cognition Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

Cognition Therapeutics' return on equity of -72.68% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
Aura Biosciences	N/A	-78.12%	-64.08%

43.4% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 14.4% of Cognition Therapeutics shares are owned by company insiders. Comparatively, 6.3% of Aura Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cognition Therapeutics presently has a consensus price target of $3.33, suggesting a potential upside of 177.78%. Aura Biosciences has a consensus price target of $20.00, suggesting a potential upside of 150.63%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Cognition Therapeutics is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Cognition Therapeutics beats Aura Biosciences on 9 of the 12 factors compared between the two stocks.

How does Cognition Therapeutics compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

Atea Pharmaceuticals has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market.

Cognition Therapeutics has a consensus price target of $3.33, suggesting a potential upside of 177.78%. Given Cognition Therapeutics' higher possible upside, analysts plainly believe Cognition Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 18.1% of Atea Pharmaceuticals shares are owned by insiders. Comparatively, 14.4% of Cognition Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Cognition Therapeutics had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 10 mentions for Cognition Therapeutics and 8 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.90 beat Cognition Therapeutics' score of 0.50 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cognition Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cognition Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A

Atea Pharmaceuticals' return on equity of -57.01% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
Cognition Therapeutics	N/A	-72.68%	-53.07%

Summary

Atea Pharmaceuticals beats Cognition Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Cognition Therapeutics compare to Neumora Therapeutics?

Neumora Therapeutics (NASDAQ:NMRA) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 26.9% of Neumora Therapeutics shares are owned by insiders. Comparatively, 14.4% of Cognition Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Neumora Therapeutics presently has a consensus price target of $7.67, suggesting a potential upside of 289.17%. Cognition Therapeutics has a consensus price target of $3.33, suggesting a potential upside of 177.78%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Neumora Therapeutics is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.56
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Cognition Therapeutics had 8 more articles in the media than Neumora Therapeutics. MarketBeat recorded 10 mentions for Cognition Therapeutics and 2 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 0.94 beat Cognition Therapeutics' score of 0.50 indicating that Neumora Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neumora Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cognition Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neumora Therapeutics has a beta of 3.02, suggesting that its stock price is 202% more volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market.

Cognition Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A

Cognition Therapeutics' return on equity of -72.68% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-181.70%	-119.15%
Cognition Therapeutics	N/A	-72.68%	-53.07%

Summary

Neumora Therapeutics beats Cognition Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Cognition Therapeutics compare to PureTech Health?

PureTech Health (NASDAQ:PRTC) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

0.0% of PureTech Health shares are held by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are held by institutional investors. 5.3% of PureTech Health shares are held by company insiders. Comparatively, 14.4% of Cognition Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cognition Therapeutics has a consensus price target of $3.33, indicating a potential upside of 177.78%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cognition Therapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Cognition Therapeutics had 8 more articles in the media than PureTech Health. MarketBeat recorded 10 mentions for Cognition Therapeutics and 2 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.94 beat Cognition Therapeutics' score of 0.50 indicating that PureTech Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cognition Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PureTech Health has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market.

Cognition Therapeutics has lower revenue, but higher earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	93.81	-$109.74M	N/A	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A

PureTech Health's return on equity of 0.00% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Cognition Therapeutics	N/A	-72.68%	-53.07%

Summary

Cognition Therapeutics beats PureTech Health on 8 of the 12 factors compared between the two stocks.

Get Cognition Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGTX vs. The Competition

Export

Metric	Cognition Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$107.40M	$3.42B	$6.34B	$12.37B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-5.00	18.47	20.66	25.63
Price / Sales	N/A	294.84	547.76	76.59
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	3.64	6.93	9.88	6.97
Net Income	-$23.49M	$24.11M	$3.55B	$333.62M
7 Day Performance	-0.83%	5.89%	1.69%	1.09%
1 Month Performance	10.09%	-0.91%	0.48%	3.08%
1 Year Performance	280.83%	74.58%	39.39%	35.68%

Cognition Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGTX Cognition Therapeutics	3.3745 of 5 stars	$1.20 flat	$3.33 +177.8%	+259.8%	$107.40M	N/A	N/A	20	Analyst Revision
CGC Canopy Growth	2.1208 of 5 stars	$1.13 +1.8%	N/A	-24.1%	$456.66M	$225.65M	N/A	3,150	Positive News
AURA Aura Biosciences	2.514 of 5 stars	$7.01 -0.6%	$21.50 +206.7%	+62.9%	$450.04M	N/A	N/A	50	Earnings Report Upcoming Earnings Analyst Forecast Analyst Revision
AVIR Atea Pharmaceuticals	1.107 of 5 stars	$5.58 +1.3%	N/A	+67.5%	$446.55M	N/A	N/A	70	Earnings Report
NMRA Neumora Therapeutics	3.6467 of 5 stars	$2.44 -1.2%	$7.67 +214.2%	+220.3%	$445.76M	N/A	N/A	108	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGTX) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cognition Therapeutics (CGTX) Competitors

CGTX vs. CGC, AURA, AVIR, NMRA, and PRTC

How does Cognition Therapeutics compare to Canopy Growth?

Summary

How does Cognition Therapeutics compare to Aura Biosciences?

Summary

How does Cognition Therapeutics compare to Atea Pharmaceuticals?

Summary

How does Cognition Therapeutics compare to Neumora Therapeutics?

Summary

How does Cognition Therapeutics compare to PureTech Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX vs. The Competition

Cognition Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cognition Therapeutics (CGTX) Competitors

CGTX vs. CGC, AURA, AVIR, NMRA, and PRTC

How does Cognition Therapeutics compare to Canopy Growth?

Which has more risk & volatility, CGTX or CGC?

Does the media favor CGTX or CGC?

Which has preferable valuation & earnings, CGTX or CGC?

Is CGTX or CGC more profitable?

Do institutionals & insiders hold more shares of CGTX or CGC?

Do analysts prefer CGTX or CGC?

Summary

How does Cognition Therapeutics compare to Aura Biosciences?

Which has more volatility & risk, CGTX or AURA?

Does the media refer more to CGTX or AURA?

Which has higher earnings and valuation, CGTX or AURA?

Is CGTX or AURA more profitable?

Do insiders and institutionals hold more shares of CGTX or AURA?

Do analysts rate CGTX or AURA?

Summary

How does Cognition Therapeutics compare to Atea Pharmaceuticals?

Which has more volatility and risk, AVIR or CGTX?

Do analysts recommend AVIR or CGTX?

Do institutionals and insiders hold more shares of AVIR or CGTX?

Does the media prefer AVIR or CGTX?

Which has better earnings & valuation, AVIR or CGTX?

Is AVIR or CGTX more profitable?

Summary

How does Cognition Therapeutics compare to Neumora Therapeutics?

Do institutionals and insiders hold more shares of NMRA or CGTX?

Do analysts recommend NMRA or CGTX?

Does the media prefer NMRA or CGTX?

Which has more volatility and risk, NMRA or CGTX?

Which has better earnings & valuation, NMRA or CGTX?

Is NMRA or CGTX more profitable?

Summary

How does Cognition Therapeutics compare to PureTech Health?

Do institutionals & insiders believe in PRTC or CGTX?

Do analysts rate PRTC or CGTX?

Does the media refer more to PRTC or CGTX?

Which has more risk & volatility, PRTC or CGTX?

Which has higher valuation & earnings, PRTC or CGTX?

Is PRTC or CGTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX vs. The Competition

Cognition Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools